# A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

> **NCT05980481** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **RemeGen Co., Ltd.** · enrollment: 201 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** RC48-ADC（2.5mg/kg）
- **DRUG:** Trastuzumab
- **DRUG:** Toripalimab
- **DRUG:** Oxaliplatin（130mg/m2 ）
- **DRUG:** Capecitabine（1000mg/m2）
- **DRUG:** RC48-ADC（2.0mg/kg）
- **DRUG:** Capecitabine（750mg/m2）
- **DRUG:** Oxaliplatin（100mg/m2 ）

## Key facts

- **NCT ID:** NCT05980481
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-04
- **Primary completion:** 2025-07-10
- **Final completion:** 2026-10-10
- **Target enrollment:** 201 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05980481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05980481, "A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05980481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*